Ansun Biopharma Announces Late Breaker Oral Presentation At ICAAC On The Clinical Activity Of Paradase™, An Investigational Drug For The Treatment Of Severe Parainfluenza Infection

SAN DIEGO--(BUSINESS WIRE)--Ansun BioPharma announced today a late breaker oral presentation titled “DAS181 for the Treatment of Parainfluenza Virus Infections in 16 Hematopoietic Stem Cell Transplant Recipients” by Dr. Mirella Salvatore of Weill Cornell Medical College. The presentation examined the safety, clinical and virologic outcomes of transplant patients infected with the parainfluenza virus and treated with DAS181 (ParaDase™).

Help employers find you! Check out all the jobs and post your resume.